Gene and Molecular Pathway Characterization of the Response to Ozone Treatment in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Radio-chemotherapy

What this Trial Is About

Gynecological cancers, including ovarian, uterine, and cervical cancers, pose a significant health challenge for women. Many survivors experience chronic pelvic pain caused by treatments like radiotherapy and chemotherapy, which can be difficult to manage and can greatly reduce quality of life. Researchers are studying how ozone therapy might influence gene expression and epigenetic markers to better understand and possibly predict pain relief in these patients. This observational and prospective study involves two groups of adult women with gynecological tumors treated by radiotherapy/chemotherapy: those with chronic pelvic pain who receive compassionate or palliative ozone therapy, and those without this pain. No interventions beyond standard care are applied to the group without pain. The study aims to analyze differences between these groups at the start and after 16 weeks, focusing on gene expression and biological age assessed by epigenetic clocks. Participants will be assessed at baseline and after 16 weeks of ozone therapy if applicable. Researchers will measure gene expression, epigenetic biological age, pain levels, toxicity grades, quality of life, and biochemical markers of oxidative stress and inflammation. The study duration extends to August 2027, with comprehensive monitoring to evaluate the molecular and clinical effects of ozone therapy in managing treatment-induced chronic pelvic pain.

Gene and Molecular Pathways of Ozone Treatment Response in Gynecological Tumor Patients With Chronic Pelvic Pain Secondary to Cancer Treatment